Frazier Life Sciences (FLS) has announced the addition of Adam Simpson as Venture Partner in its Company Creation team. Simpson, an industry veteran with 25 years of experience, has helped build 11 companies that have been acquired or gone public. He most recently served as CEO of Icosavax (Nasdaq: ICVX), leading it through its IPO and subsequent acquisition by AstraZeneca. Simpson's expertise includes team building, advancing novel technologies through clinical proof-of-concept, and leading significant fundraising, partnerships, and acquisitions. At FLS, he will support new company innovation and portfolio company growth, leveraging his financial, operational, and emerging company knowledge.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.